| abstract |
Disclosed is the use of a construct comprising a virus-like particle (VLP) structure chemically coupled to a fragment of the Ab-1-42 peptide, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the prevention or treatment of dementia in humans, wherein the pharmaceutical composition is formulated for subcutaneous administration at a dose of 150 ìg to 1000 ìg of the construct about every 4 to 8 weeks, and wherein the fragment of Ab-1-42 peptide is Ab-1-6 peptide. |